BRISBANE, Calif., May 12, 2026
Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948) has been selected for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), scheduled to take place in Stockholm, Sweden, from June 11–14, 2026. The oral presentation will highlight updated efficacy and safety findings from the ongoing Phase 1a/b clinical trial evaluating bexobrutideg in patients with chronic lymphocytic leukemia (CLL) across multiple lines of therapy. The acceptance of the abstract for oral presentation reflects growing scientific and clinical interest in targeted protein degradation therapeutics, an emerging area of precision medicine designed to eliminate disease-causing proteins rather than simply inhibit their activity. Nurix believes bexobrutideg may offer a differentiated therapeutic approach for patients with relapsed or refractory B-cell malignancies, particularly those who develop resistance to existing BTK inhibitor therapies.
Bexobrutideg Advances Next-Generation BTK Targeting
According to Nurix Therapeutics, bexobrutideg is an investigational, orally bioavailable, highly selective and brain-penetrant Bruton’s tyrosine kinase (BTK) degrader engineered to eliminate BTK protein through targeted degradation mechanisms. Unlike traditional BTK inhibitors that block kinase activity, targeted protein degraders are designed to induce destruction of the BTK protein itself, potentially overcoming resistance mutations and improving durability of response in hematologic cancers. BTK signaling remains a critical driver of several B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, and other lymphoid cancers.
The EHA2026 oral presentation will feature updated clinical findings from the ongoing NX-5948-301 Phase 1a/1b study, which is evaluating bexobrutideg in patients with relapsed or refractory B-cell malignancies. The company stated that the presentation will focus specifically on patients with CLL treated across different therapy lines, providing updated safety and efficacy analyses. Growing interest in next-generation BTK-targeted therapies has intensified as resistance and intolerance continue emerging among patients receiving first-generation and second-generation BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib.
Nurix is also advancing the pivotal DAYBreak CLL-201 Phase 2 clinical trial, a single-arm registrational study evaluating bexobrutideg in patients with relapsed or refractory CLL. Industry analysts believe successful development of BTK degraders could significantly reshape treatment strategies within hematologic oncology by addressing acquired resistance mutations that reduce effectiveness of conventional kinase inhibitors. The brain-penetrant properties of bexobrutideg may additionally create opportunities for treating malignancies involving central nervous system involvement, an area where many BTK inhibitors demonstrate limited therapeutic exposure.
Targeted Protein Degradation Gains Momentum in Oncology
Advertisement
The EHA2026 presentation reflects broader momentum across the rapidly expanding field of targeted protein degradation, one of the biotechnology industry’s most closely watched therapeutic platforms. Unlike traditional small molecules that inhibit protein activity, degraders utilize cellular protein recycling systems to selectively eliminate disease-driving proteins entirely. Researchers believe this strategy may expand the range of “druggable” targets while improving therapeutic potency and reducing resistance development across cancer and autoimmune diseases.
Nurix Therapeutics has positioned itself among the leading biotechnology companies developing degrader-based medicines through its proprietary AI-integrated discovery platform and deep expertise in E3 ligase biology. In addition to BTK degraders, the company’s internal pipeline includes programs targeting CBL-B, an intracellular regulator involved in immune cell activation pathways affecting T cells and natural killer cells. Nurix is also developing multiple degrader antibody conjugates (DACs) and next-generation precision oncology therapies designed to selectively eliminate pathogenic proteins in cancer cells.
The company has established several major pharmaceutical collaborations supporting development of degrader-based therapeutics, including partnerships with Sanofi, Gilead Sciences, and Pfizer. Current partnered programs include degraders targeting STAT6 and IRAK4, alongside multiple undisclosed discovery-stage collaborations. These partnerships highlight increasing pharmaceutical investment in targeted protein degradation technologies as companies seek next-generation therapeutic modalities capable of addressing previously difficult-to-target diseases.
Nurix Strengthens Position in Precision Hematology Therapies
The updated bexobrutideg data presented at EHA2026 are expected to further strengthen Nurix’s position within the highly competitive hematology and targeted oncology market. Chronic lymphocytic leukemia remains the most common adult leukemia in Western countries, and while BTK inhibitors have transformed patient outcomes over the past decade, resistance mutations and disease progression continue creating substantial unmet medical need.
Nurix executives stated that the company’s broader goal is to establish degrader-based medicines at the forefront of future patient care through highly selective protein elimination strategies supported by precision molecular engineering. As biotechnology companies increasingly pursue therapies capable of overcoming treatment resistance and improving long-term disease control, Nurix aims to position its degrader platform among the leading next-generation therapeutic technologies advancing precision oncology and immune-mediated disease treatment.
Source: Nurix Therapeutics press release
